A novel adjuvant drug-device combination tissue scaffold for radical prostatectomy.
In conclusion, this study demonstrates the concept of combining docetaxel with the biodegradable microparticles at the point of care is technically feasible for achieving an effective drug-device combination tissue scaffold. This approach could provide an effective new approach for delivering adjuvant chemotherapy following radical prostatectomy. PMID: 31735095 [PubMed - in process]
Condition: Prostate Cancer Interventions: Drug: Niraparib; Drug: Leuprolide; Drug: Abiraterone Acetate; Radiation: Stereotactic body radiotherapy (SBRT) Sponsors: University of Michigan Rogel Cancer Center; Janssen Scientific Affairs, LLC Not yet recruiting
PROSTATE cancer is the most common cancer in men in the UK and treatment outcomes depend greatly on how early it is caught. The warning signs associated with the disease are associated with the bladder and men who experience a certain issue in cold weather should not rule out the disease.
Short-term exercise may help reduce the adverse side effects of hormone therapy for patients with prostate cancer, according to a study published in theBritish Journal of Urology International (BJUI).Science Daily
Authors: Chen YF, Liang YX, Yang JA, Yuan DZ, Li J, Zheng SS, Wan YP, Wang B, Han ZD, Zhong WD Abstract Abnormal expression of Holliday junction recognition protein (HJURP) in several types of tumor cells plays a vital role in the formation and progression of tumors. Few studies have investigated the role of HJURP in prostate cancer (PCa). The aim of this study was to analyze the expression levels of HJURP in PCa and to establish the association with clinicopathological data. Reverse transcription quantitative polymerase chain reaction and immunohistochemical analysis were used to detect the expression levels of HJ...
Conclusion: Enzalutamide can be used to effectively treat mCRPC patients in daily clinical settings, despite the patients being older and less healthy than those enrolled in the previous randomised, clinical registration studies. PMID: 31815592 [PubMed - in process]
Prostate Cancer and Prostatic Diseases, Published online: 11 December 2019; doi:10.1038/s41391-019-0196-4Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study
Publication date: Available online 9 December 2019Source: Reports of Practical Oncology &RadiotherapyAuthor(s): A. Zapatero, M. Adrados, L. Torres, M.S. Talaya, A. Cruz Conde, C. Martin de Vidales, L. Vega Piris, C. Olivier, M.T. MurilloABSTRACTBackground/aim(s)To determine the impact of post-treatment biopsy results on 10-year metastasis-free survival (MFS), overall survival (OS) and cause-specific survival (CSS) in localized prostate cancer (PCa) patients treated with high-dose radiotherapy (RT).Materials/MethodsRetrospective analysis of 232 patients with T1c-T3bN0M0 PCa who underwent a prostate biopsy 24–36 mo...
Conclusion: Our results were not able to show any significant correlation between increasing convenience with QUANTEC limits and lower rectal toxicity. Conclusively, new dosimetric definitions are warranted to predict acute rectal toxicity more accurately in prostate cancer patients during IMRT treatment.
Noncanonical Wnt as a prognostic marker in prostate cancer: "You can't always get what you Wnt". Expert Rev Mol Diagn. 2019 Dec 07;: Authors: Fisher RR, Pleskow HM, Bedingfield K, Miyamoto DT Abstract Introduction: Wnt signaling is important for normal development, cell proliferation, and cell differentiation. However, aberrations in the pathway can lead to tumorigenesis and cancer progression. Recent genome-wide studies have demonstrated the frequent occurrence of Wnt pathway alterations in prostate cancer. Although alterations in the canonical Wnt pathway in prostate cancer may have an impa...